An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 333-336

  Prajapati, Vijay Kumar ^a   Awasthi, Kalpna ^b   Yadav, Thakur Prasad ^b   Rai, Madhukar ^a   Srivastava, Onkar Nath ^b   Sundar, Shyam ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CARBON NANOTUBE; MILTEFOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; EXPERIMENTAL INFECTION; IN VIVO STUDY; LEISHMANIA DONOVANI; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYRIAN HAMSTER; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CRICETINAE; DRUG CARRIERS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; NANOTUBES, CARBON; PARASITE LOAD; SPLENIC DISEASES;

EID: 84555186965     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir735     Document Type: Article

References (14)

1. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7. (Pubitemid 32299375)
2. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-12.
3. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93:319-23. (Pubitemid 29348832)
4. Boelaert M, Meheus F, Sanchez A, et al. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009; 14:639-44.
5. Delmas G, Park S, Chen ZW, et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 2002; 46:2704-7. (Pubitemid 34793493)
6. Wasan KM, Wasan EK, Gershkovich P, et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 2009; 200:357-60.
7. Golenser J, Domb A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini Rev Med Chem 2006; 6:153-62.
8. Prajapati VK, Awasthi K, Gautam S, et al. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother 2010; 66:874-9.
9. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008; 41:60-8.
10. Chen RJ, Zhang Y, Wang D, Dai H. Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J Am Chem Soc 2001; 123:3838-9. (Pubitemid 32879553)
11. Pantarotto D, Briand JP, Prato M, Bianco A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb) 2004; 1:16-17. (Pubitemid 38121939)
12. Georgakilas V, Kordatos K, Prato M, Guldi DM, Holzinger M, Hirsch A. Organic functionalization of carbon nanotubes. J Am Chem Soc 2002; 124:760-1. (Pubitemid 34112779)
13. Maurya R, Mehrotra S, Prajapati VK, Nylen S, Sacks D, Sundar S. Evaluation of blood agar microtiter plates for culturing Leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol 2010; 48:1932-4.
14. Manandhar KD, Yadav TP, Prajapati VK, et al. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother 2008; 62:376-80. (Pubitemid 351984784)